Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) Cash & Current Investments (2016 - 2025)

Tvardi Therapeutics' Cash & Current Investments history spans 13 years, with the latest figure at $30.8 million for Q4 2025.

  • On a quarterly basis, Cash & Current Investments fell 2.47% to $30.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $30.8 million, a 2.47% decrease, with the full-year FY2025 number at $30.8 million, down 2.47% from a year prior.
  • Cash & Current Investments hit $30.8 million in Q4 2025 for Tvardi Therapeutics, down from $36.4 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for TVRD hit a ceiling of $171.6 million in Q1 2021 and a floor of $30.8 million in Q4 2025.
  • Historically, Cash & Current Investments has averaged $94.9 million across 5 years, with a median of $86.6 million in 2023.
  • The widest YoY moves for Cash & Current Investments: up 45.97% in 2024, down 68.62% in 2024.
  • Tracing TVRD's Cash & Current Investments over 5 years: stood at $167.0 million in 2021, then decreased by 12.95% to $145.4 million in 2022, then tumbled by 30.7% to $100.8 million in 2023, then crashed by 68.62% to $31.6 million in 2024, then fell by 2.47% to $30.8 million in 2025.
  • Business Quant data shows Cash & Current Investments for TVRD at $30.8 million in Q4 2025, $36.4 million in Q3 2025, and $40.9 million in Q2 2025.